Information Provided By:
Fly News Breaks for September 19, 2018
PCRX
Sep 19, 2018 | 06:36 EDT
RBC Capital analyst Randall Stanicky raised his price target on Pacira to $55 and kept his Buy rating after meeting with its management, saying the discussion gave him more confidence about the company's continued profitability momentum and more tailwinds coming in 2019. The analyst cites Pacira's efforts to achieve a broader label for EXPAREL, expansion of its r Ambulatory Surgery Center presence, and the confidence that it will "receive a J-code for EXPAREL" on January 1st.
News For PCRX From the Last 2 Days
There are no results for your query PCRX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.